Zacks bearish on Ritter Pharma; shares slump 17%

|About: Ritter Pharmaceuticals (RTTR)|By:, SA News Editor

Thinly traded nano cap Ritter Pharmaceuticals (RTTR -17.1%) is down on triple normal volume on the heels of a downgrade to Sell by Zacks Investment Research.

Perennial bulls Aegis, Roth Capital and Maxim Group have Buy ratings on the stock with price targets of $9 (420% upside), $6 (228% upside) and $5 (173% upside), respectively. Chardan Capital also rates it a Buy with a fair value target of $5.

Data from a Phase 2b/3 clinical trial assessing lead product candidate RP-G28 for the treatment of lactose intolerance are expected any time.

Previously: Monitoring visits completed in Ritter's late-stage study of lead product candidate RP-G28, top-line data expected in Q1; shares up 24% (Oct. 18, 2016)